본문영역 바로가기
ABL Bio - medicine for A Better Life
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
KOR
ENG
모바일 메뉴 보기
Investors & Media
News
Home
Investors & Media
News
No data is registered.
list
PREV
NEXT
ABL Bio Adopts Novel Bispecific Antibody Platform and Two Types of Immuno-Oncology Targeted Antibody
ABL Bio
About Us
Who We Are
History
Corporate Identity
Leadership
Contact Us
Platform & Strategies
Platform
Oncology Strategy
CNS Disease Strategy
ADC Strategy
Publications
Pipeline
Overview
ABL301
ABL503
ABL111
ABL102
ABL103
ABL104
ABL105
ABL501
Investors & Media
Public Disclosure
Stock Information
Finance Information
Notice
News
Document & Materials
Careers
Core Competencies
Benefits
Recruitment
Recruiting Process
메뉴닫기